IGM Biosciences Inc (NAS:IGMS)

$ 16.38 -1.07 (-6.21%) Market Cap: 958.59 Mil Enterprise Value: 807.42 Mil PE Ratio: 0 PB Ratio: 8.36 GF Score: 34/100

IGM Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
IGM Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
IGM Biosciences Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
IGM Biosciences Inc Clinical Update Conference Call Transcript
Jun 02, 2023
IGM Biosciences Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
IGM Biosciences Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023
Q4 2022 IGM Biosciences Inc Earnings Call Transcript
Mar 30, 2023

$17.02 (-1.45%)

Earnings
IGM Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
IGM Biosciences Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 08, 2022
IGM Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
IGM Biosciences Inc Annual Shareholders Meeting Transcript
Jun 21, 2022
IGM Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022
IGM Biosciences Inc to Discuss Global Collaboration Agreement with Sanofi - Conference Call Transcript
Mar 29, 2022
IGM Biosciences Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
IGM Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
IGM Biosciences Inc to Discuss IGMS ASH Data - Conference Call Transcript
Dec 12, 2021
IGM Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
IGM Biosciences Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021
IGM Biosciences Inc at Truist Securities Life Sciences Summit (May Series) Transcript
May 04, 2021
Q4 2020 IGM Biosciences Inc Earnings Call Transcript
Mar 30, 2021

$75.06 (+1.86%)

Earnings
IGM Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call Transcript
Jan 12, 2021
IGM Biosciences Inc Review of IGM-2323 Data Presented at the 62nd Annual ASH Meeting - Conference Call Transcript
Dec 05, 2020
IGM Biosciences Inc at Wolfe Research Healthcare Conference (Virtual) Transcript
Nov 18, 2020
IGM Biosciences Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 17, 2020
IGM Biosciences Inc at Stifel Virtual Healthcare Conference Transcript
Nov 16, 2020
IGM Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 18, 2020
IGM Biosciences Inc Extraordinary Shareholders Meeting Transcript
Jul 30, 2020
IGM Biosciences Inc Annual Shareholders Meeting Transcript
Jun 09, 2020
Q4 2019 IGM Biosciences Inc Earnings Call Transcript
Mar 26, 2020

$43 (-9.11%)

Earnings
IGM Biosciences Inc at Barclays Global Healthcare Conference Transcript
Mar 11, 2020

IGM Biosciences Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 08, 2022 / 07:45PM GMT

Release Date Price: $20.28 (+2.53%)

Transcript

Operator

The program is about to begin. (Operator Instructions) At this time, it is my pleasure to turn the program over to your host, Greg Harrison.

Gregory Allen Harrison

BofA Securities, Research Division - Analyst

Hi and welcome to the Bank of America SMID Biotech Virtual Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, I'm happy to introduce IGM Biosciences represented by Fred Schwarzer, CEO. Thanks for joining us, everybody. And for those of you out there watching, if you'd like to send any questions, I'm happy to ask them on your behalf.

Questions & Answers

Gregory Allen Harrison;Fred M. Schwarzer

BofA Securities, Research Division - Analyst;IGM Biosciences, Inc. - CEO, President &

Fred, let's go ahead and just jump right into the Q&A. Maybe just with an intro for people who maybe are less up to speed on IGM, what is differentiating about the IGM class of antibodies as therapeutics relative to traditional IgG antibody treatment?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.